Disease Elimination Program, Burnet Institute, Melbourne, Australia.
Department of Medicine, The University of Melbourne, Melbourne, Australia.
Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Australia.
Department of Infectious Diseases, University Hospital and University of Bern, Bern, Switzerland.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
The Kirby Institute, University of New South Wales, Sydney, Australia.
Public Health Service Amsterdam, Amsterdam, the Netherlands.
International Antiviral Therapy Evaluation Center and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, Amsterdam, the Netherlands.
Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
Infectious Diseases, AP-HP, Sorbonne Universités and Inserm UMR-S1136, Paris, France.
Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA.
Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Centre of Excellence in Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia.
There is currently no published data on the effectiveness of DAA treatment for elimination of HCV infection in HIV-infected populations at a population level. However, a number of relevant studies and initiatives are emerging. This research aims to report cascade of care data for emerging HCV elimination initiatives and studies that are currently being evaluated in HIV/HCV co-infected populations in the context of implementation science theory.
HCV elimination initiatives and studies in HIV co-infected populations that are currently underway were identified. Context, intervention characteristics and cascade of care data were synthesized in the context of implementation science frameworks.
Seven HCV elimination initiatives and studies were identified in HIV co-infected populations, mainly operating in high-income countries. Four were focused mainly on HCV elimination in HIV-infected gay and bisexual men (GBM), and three included a combination of people who inject drugs (PWID), GBM and other HIV-infected populations. None were evaluating treatment delivery in incarcerated populations. Overall, HCV RNA was detected in 4894 HIV-infected participants (range within studies: 297 to 994): 48% of these initiated HCV treatment (range: 21% to 85%; within studies from a period where DAAs were broadly available the total is 57%, range: 36% to 74%). Among studies with treatment completion data, 96% of 1109 initiating treatment completed treatment (range: 94% to 99%). Among those who could be assessed for sustained virological response at 12 weeks (SVR12), 1631 of 1757 attained SVR12 (93%, range: 86% to 98%).
Early results from emerging research on HCV elimination in HIV-infected populations suggest that HCV treatment uptake is higher than reported levels prior to DAA treatment availability, but approximately half of patients remain untreated. These results are among diagnosed populations and additional effort is required to increase diagnosis rates. Among those who have initiated treatment, completion and SVR rates are promising. More data are required in order to evaluate the effectiveness of these elimination programmes in the long term, assess which intervention components are effective, and whether they need to be tailored to particular population groups.